Physician profile
Deepthi Sudhakar
NPI 1811307051
$31,392.76
in general payments reported to CMS, 2019-2025
41 companies · $5,600 in 2025
The $5,600 reported for 2025 was more than what 84% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,371 · 2020: $2,386 · 2021: $3,496 · 2022: $4,863 · 2023: $5,897 · 2024: $4,779 · 2025: $5,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $2,218 · Education: $7.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,051.72 |
| Travel and Lodging | $2,217.98 |
| Education | $7.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,484.83 | 2019-2025 | Cardiomems, Aveir, Xience Skypoint |
| Boston Scientific Corporation | $3,587.76 | 2019-2025 | Avvigo Guidance System, Watchman Flx, Versacross Access Solution |
| Shockwave Medical, INC | $3,389.69 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Medical L6 Intravascular Lithotripsy (Ivl) Catheter |
| Edwards Lifesciences Corporation | $3,023.10 | 2021-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $2,998.40 | 2021-2025 | Onyx Frontier, Resolute Onyx, Symplicity G3 |
| Abiomed | $2,044.44 | 2019-2025 | Impella |
| Asahi Intecc USA, INC. | $893.97 | 2023-2025 | Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Asahi Ptca Guide Wire |
| Reflow Medical INC | $662.75 | 2024-2025 | |
| Amgen INC. | $569.83 | 2019-2024 | Repatha |
| Cardiva Medical, INC. | $471.14 | 2021-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade 6/7f Vcs |
| Heartflow, INC. | $454.07 | 2024-2025 | |
| Biotronik INC. | $418.01 | 2019-2023 | Nhancer Rx, Trapit |
| Novo Nordisk INC | $322.36 | 2022-2025 | Ozempic, Rybelsus |
| Verge Medical, INC. | $292.20 | 2024 | |
| Inari Medical, INC. | $279.54 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Sudhakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.